All Articles

A large cohort analysis of treatment status, treatment regimen, and outcomes in patients with KRAS-mutated advanced NSCLC revealed valuable information for future clinical trials.

Nivolumab Combined with Chemotherapy Improves Survival Outcome in Patients with Advanced Gastric/Esophageal Cancers

Gastrointestinal Cancers

Web Exclusives

CheckMate 649 study results demonstrate that nivolumab combined with chemotherapy has an acceptable safety profile and improves survival outcomes in patients with advanced gastric/esophageal cancer.

Second-Line Pembrolizumab Therapy Conveys Survival Benefit in Patients with Advanced Esophageal Cancer

Gastrointestinal Cancers

Web Exclusives

Japanese study data demonstrate second-line pembrolizumab improved overall survival with an acceptable safety profile compared with chemotherapy in patients with advanced esophageal cancer.

ASCO Clinical Practice Guidelines for Clinician Management of Patients with Advanced Esophageal Cancer

Gastrointestinal Cancers

Web Exclusives

An expert panel released recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma.

CheckMate 648 Study Data Indicate Improved Overall Survival for Patients with Advanced Esophageal Squamous-Cell Carcinoma Treated with Nivolumab and Ipilimumab or Chemotherapy

Gastrointestinal Cancers

Web Exclusives

Nivolumab added to either ipilimumab or chemotherapy improved overall survival in patients with advanced esophageal squamous-cell carcinoma, according to data from the CheckMate-648 study.

Immune Checkpoint Analysis in Gastric Adenocarcinoma

Gastrointestinal Cancers

Web Exclusives

A comprehensive analysis of immune checkpoints in gastric adenocarcinoma found that ICOSLG and CD70 are associated with immune infiltration and may potentially serve as prognostic biomarkers.

Second-Line Trastuzumab Deruxtecan in Patients with Metastatic Gastric or Esophageal Junction Cancer Demonstrates Clinical Efficacy

Gastrointestinal Cancers

Web Exclusives

Phase 2 study results of second-line trastuzumab deruxtecan use in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer revealed an antitumor response.

PET/CT Imaging in Prostate Cancer Patients

Overview of Current Imaging Modalities in Prostate Cancer

By Neal D. Shore, MD

Interview with the Innovators

Video Library

Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY^® (piflufolastat F 18).

Diagnostic Capability in Relapsed Prostate Cancer Improved with ¹⁸F-DCFPyL PET/CT Imaging

Prostate Cancer

Web Exclusives

Recently released analysis of ¹⁸F-DCFPyL PET/CT accuracy demonstrated improved diagnostic capability in men with biochemical recurrence of prostate cancer.

NaF PET Imaging Demonstrates Increased Sensitivity for New Lesion Detection for Patients with Metastatic Prostate Cancer

Prostate Cancer

Web Exclusives

NaF PET imaging study demonstrates an increased sensitivity over Tc99m-MDP bone scans for new lesion detection in patients with stable metastatic prostate cancer.

All Articles

Page 96 of 281

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.